SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of February 4, 1991 (56 FR 4295), FDA announced that a food additive petition (FAP 1B4241) had been filed on behalf of Milliken & Co., P.O. Box 1927 M-400, Spartanburg, SC 29304 (currently c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001). The petition proposed to amend the food additive regulations in § 178.3295 Clarifying agents for polymers (21 CFR 178.3295) to provide for the safe expanded use of DBS as a clarifying agent for olefin polymers intended for use in contact with food. Milliken & Co. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: March 18, 1996.

George H. Pauli,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–7677 Filed 3–28–96; 8:45 am]

National Institutes of Health

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Prevention Program Working Group, April 17, 1996 at The Bethesda Ramada, 8400 Wisconsin Avenue, Bethesda, Maryland.

This meeting will be open to the public on April 17, from 8 a.m. to 3:30 p.m. for overview and discussion of the Institute's Prevention Program.

The meeting will be closed to the public on April 17, from 3:45 p.m. to adjournment for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the Clinical Trials Extramural Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. Jack Gruber, Executive Secretary, National Cancer Institute Prevention Program Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892, (301–496–9740). Individuals who plan to attend and

need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. Jack Gruber in advance of the meeting.

Dated: March 25, 1996. Susan K. Feldman, Committee Management Officer, NIH. [FR Doc. 96–7725 Filed 3–28–96; 8:45 am] BILLING CODE 4140–01–M

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: NCI Initial Review Group, Subcommittee D (Clinical Studies).

Date: April 12, 1996. Time: 8:00 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814. Contact Person: John W. Abrell, Ph.D., 6130 Executive Blvd., Room 635B, Bethesda,

Md 20892. Telephone: 301-496-9767. The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: March 25, 1996. Susan K. Feldman, Committee Management Officer, NIH. [FR Doc. 96–7726 Filed 3–28–96; 8:45 am] BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Refinement of New Assays for Direct Detection of Viral Nucleic Acids in Donated Blood.

Date: April 11, 1996.

Time: 7:30 p.m.

Place: Ramada Inn, 1775 Rockville Pike, Rockville, Maryland.

Contact Person: Ivan Baines, Ph.D., Two Rockledge Center, Room 7184, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0277.

Purpose/Agenda: To review and evaluate contract proposals.

Name of SEP: Refinement of New Assays for Direct Detection of Viral Nucleic Acids in Donated Organs.

Date: April 12, 1996.

Time: 8:00 a.m.

Place: Ramada Inn, 1775 Rockville Pike, Rockville, Maryland.

Contact Person: Ivan Baines, Ph.D., Two Rockledge Center, Room 7184, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0277.

Purpose/Agenda: To review and evaluate contract proposals.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the above meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 25, 1996. Susan K. Feldman, Committee Management Officer, NIH. [FR Doc. 96–7223 Filed 3–28–96; 8:45 am] BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Strong Heart Study Renewal Application.

Date: April 18, 1996.

Time: 1:00 p.m.

Place: Residence Inn by Marriott, Bethesda, Maryland.

Contact Person: David M. Monsees, Ph.D., Rockledge II, Room 7178, 6701 Rockledge Drive, Bethesda, Maryland 20892–7924, (301) 435–0270.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Pathways—Full Scale Study. *Date:* April 18, 1996.